Qianqian Yu,Hong Qiu,Mingsheng Zhang,Guangyuan Hu,Liu Huang,Xianglin Yuan. Prognostic value of the neutrophil-to-lymphocyte ratio in metastatic colorectal cancer*. Oncol Transl Med, 2016, 2: 75-79. |
Prognostic value of the neutrophil-to-lymphocyte ratio in metastatic colorectal cancer* |
Received:January 09, 2016 Revised:April 06, 2016 |
View Full Text View/Add Comment Download reader |
KeyWord:metastatic colorectal cancer (mCRC); outcome; neutrophil-to-lymphocyte ratio (NLR) |
Author Name | Affiliation | E-mail | Qianqian Yu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | yqq0258@163.com | Hong Qiu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | tjqiuhong@163.com | Mingsheng Zhang | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | zms75@163.com | Guangyuan Hu | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | h.g.y.121@163.com | Liu Huang | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | huangliu017@163.com | Xianglin Yuan | Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China | yxl@medmail.com.cn |
|
Hits: 6727 |
Download times: 7349 |
Abstract: |
Objective?This study investigated the prognostic value of the neutrophil-to-lymphocyte ratio (NLR) in predicting clinical outcomes of patients with metastatic colorectal cancer (mCRC) undergoing irinotecan-based first-line chemotherapy.
Methods?This study was based on a Chinese prospective multicenter trial (NCT01282658). Baseline complete blood cell counts were performed. Survival was determined using the Kaplan-Meier method. Multivariate analyses based on the Cox regression model were performed to determine the effects of independent biomarkers.
Results?A total of 139 patients were evaluated. Values below the median NLR were associated with better progression-free survival (PFS) (9.9 vs 7.7 months, P = 0.043) and overall survival (OS) (21.8 vs 15.1 months, P = 0.013). These effects remained significant in multivariate analysis.
Conclusion?NLR is an independent prognostic marker of mCRC treated with first-line irinotecan-based therapy in a Chinese population.
|
Close |
|
|
|